Search Results - "Klümpen, H."

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Vogel, A., Bridgewater, J., Edeline, J., Kelley, R.K., Klümpen, H.J., Malka, D., Primrose, J.N., Rimassa, L., Stenzinger, A., Valle, J.W., Ducreux, M.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing biliary tract cancer.•The guideline covers clinical and pathological…”
Get full text

Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA) by Heidsma, C M, Engelsman, A F, van Dieren, S, Stommel, M W J, de Hingh, I, Vriens, M, Hol, L, Festen, S, Mekenkamp, L, Hoogwater, F J H, Daams, F, Klümpen, H-J, Besselink, M G, van Eijck, C H, Nieveen van Dijkum, E J

“…This prospective nationwide cohort study examined the feasibility of a watchful-waiting protocol for non-functional pancreatic neuroendocrine tumours (NF-pNET)…”
Get full text

Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67 by Genç, C. G., Falconi, M., Partelli, S., Muffatti, F., van Eeden, S., Doglioni, C., Klümpen, H. J., van Eijck, C. H. J., Nieveen van Dijkum, E. J. M.

“…Background Despite evidence of different malignant potentials, postoperative follow-up assessment is similar for G1 and G2 pancreatic neuroendocrine tumors…”
Get full text

Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience by Rassam, F., Roos, E., van Lienden, K. P., van Hooft, J. E., Klümpen, H. J., van Tienhoven, G., Bennink, R. J., Engelbrecht, M. R., Schoorlemmer, A., Beuers, U. H. W., Verheij, J., Besselink, M. G., Busch, O. R., van Gulik, T. M.

“…Aim Perihilar cholangiocarcinoma (PHC) is a challenging disease and requires aggressive surgical treatment in order to achieve curation. The assessment and…”
Get full text

Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662 by Diekstra, M H M, Klümpen, H J, Lolkema, M P J K, Yu, H, Kloth, J S L, Gelderblom, H, van Schaik, R H N, Gurney, H, Swen, J J, Huitema, A D R, Steeghs, N, Mathijssen, R H J

“…Interpatient variability in the pharmacokinetics (PK) of sunitinib is high. Single nucleotide polymorphisms (SNPs) in PK candidate genes have been associated…”
Get full text

Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe by Lamarca, A., Morfouace, M., Tejpar, S., Oliveira, J., Capela, A., Penel, N., Gennigens, C., Brasiuniene, B., Peron, J., Stevovic, A., Blay, J.-Y., Klümpen, H.-J.

Get full text

Endoscopically removed rectal NETs: a nationwide cohort study by Kuiper, Teaco, van Oijen, M. G. H., van Velthuysen, M. F., van Lelyveld, N., van Leerdam, M. E., Vleggaar, F. D., Klümpen, H. J.

“…Purpose Rectal neuroendocrine tumours (NETs) often present as an incidental finding during colonoscopy. Complete endoscopic resection of low-grade NETs up to…”
Get full text

Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) by Casadio, M., Cardinale, V., Klümpen, H.-J., Morement, H., Lacasta, A., Koerkamp, B.G., Banales, J., Alvaro, D., Valle, J.W., Lamarca, A.

“…Cholangiocarcinomas (CCAs) are a rare group of malignancies characterized by dismal prognosis. There are currently no standardized guidelines for…”
Get full text

Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract by Roos, E., Soer, E.C., Klompmaker, S., Meijer, L.L., Besselink, M.G., Giovannetti, E., Heger, M., Kazemier, G., Klümpen, H.J., Takkenberg, R.B., Wilmink, H., Würdinger, T., Dijk, F., van Gulik, T.M., Verheij, J., van de Vijver, M.J.

“…[Display omitted] •First systematic review to assess the mutational spectrum of biliary tract cancer.•The different anatomical subtypes of biliary tract cancer…”
Get full text

European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN by Blay, J.-Y., Casali, P., Bouvier, C., Dehais, C., Galloway, I., Gietema, J., Halámková, J., Hindi, N., Idbaih, A., Kinloch, E., Klümpen, H.-J., Kolarova, T., Kopeckova, K., Lovey, J., Magalhaes, M., Oselin, K., Piperno-Neumann, S., Ravnsbaek, A., Rogasik, M., Safwat, A., Scheipl, S., Seckl, M., Taylor, J., Temnyk, M., Trama, A., Urbonas, M., Wartenberg, M., Weinman, A.

Get full text

Value of routine intraoperative frozen sections of proximal bile duct margins in perihilar cholangiocarcinoma, a retrospective multicenter and matched case-control study by Nooijen, L.E., Franken, L.C., de Boer, M.T., Buttner, S., van Dieren, S., Koerkamp, B. Groot, Hoogwater, F.J.H., Kazemier, G., Klümpen, H.J., Kuipers, H., Olthof, P.B., Swijnenburg, R.J., Verheij, J., Zonderhuis, B.M., van Gulik, T.M., Erdmann, J.I.

“…Currently, the potential benefits of additional resection after positive proximal intraoperative frozen sections (IFS) in perihilar cholangiocarcinoma (pCCA)…”
Get full text

Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework by de Hosson, L.D., van Veenendaal, L.M., Schuller, Y., Zandee, W.T., de Herder, W.W., Tesselaar, M.E.T., Klümpen, H.J., Walenkamp, A.M.E.

“…Assessment of clinical benefit of systemic treatments of rare diseases including gastroenteropancreatic neuroendocrine tumours (GEP-NET) is challenging…”
Get full text

Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) by Yau, T., Cheng, A.-L., Meyer, T., Ryoo, B.-Y., Park, J.-W., Klümpen, H.-J., Lim, H.Y., Kim, S., Knox, J., Patel, M., El-Khoueiry, A.B., Kelley, R.K., Abou-Alfa, G.K.

Get full text

Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery by Slagter, A.E, Ryder, D, Chakrabarty, B, Lamarca, A, Hubner, R.A, Mansoor, W, O’Reilly, D.A, Fulford, P.E, Klümpen, H.J, Valle, J.W, McNamara, M.G

“…Abstract Aim Surgery is the only modality of cure in patients diagnosed with neuroendocrine tumours (NETs). The aim of this study was to identify prognostic…”
Get full text

Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib by Öcal, Osman, Schinner, Regina, Schütte, Kerstin, de Toni, Enrico N, Loewe, Christian, van Delden, Otto, Vandecaveye, Vincent, Gebauer, Bernhard, Zech, Christoph J, Sengel, Christian, Bargellini, Irene, Gasbarrini, Antonio, Sangro, Bruno, Pech, Maciej, Malfertheiner, Peter, Ricke, Jens, Seidensticker, Max

“…The aim of this study was to explore the relationship between follow-up imaging characteristics and overall survival (OS) in advanced hepatocellular carcinoma…”
Get full text

Severe multiorgan failure after parvovirus B19 infection in an allogeneic stem cell transplant recipient by Klümpen, H J, Petersen, E J, Verdonck, L F

Get full text

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma by Abou-Alfa, Ghassan K, Meyer, Tim, Cheng, Ann-Lii, El-Khoueiry, Anthony B, Rimassa, Lorenza, Ryoo, Baek-Yeol, Cicin, Irfan, Merle, Philippe, Chen, YenHsun, Park, Joong-Won, Blanc, Jean-Frederic, Bolondi, Luigi, Klümpen, Heinz-Josef, Chan, Stephen L, Zagonel, Vittorina, Pressiani, Tiziana, Ryu, Min-Hee, Venook, Alan P, Hessel, Colin, Borgman-Hagey, Anne E, Schwab, Gisela, Kelley, Robin K

“…Among patients with hepatocellular carcinoma whose disease had progressed during receipt of sorafenib or other systemic therapy, median overall survival was…”
Get full text

Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer by Kordes, S., Klümpen, H. J., Weterman, M. J., Schellens, J. H. M., Richel, D. J., Wilmink, J. W.

“…Purpose The combination of an mTOR inhibitor with 5-fluorouracil-based anticancer therapy is attractive because of preclinical evidence of synergy between…”
Get full text

Effects of nutritional status on acetaminophen measurement and exposure by Achterbergh, R., Lammers, L. A., Kuijsten, L., Klümpen, H. J., Mathôt, R. A. A., Romijn, J. A.

“…Introduction: Fasting, as well as a high-fat diet, might increase the risk on acetaminophen-induced toxicity after an acute overdose. Therefore, it has been…”
Get full text

A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands by Genc, C. G., Klümpen, H. J., van Oijen, M. G. H., van Eijck, C. H. J., Nieveen van Dijkum, E. J. M.

“…Background Large population-based studies give insight into the prognosis and treatment outcomes of patients with pancreatic neuroendocrine tumors (pNETs)…”
Get full text